Ambalal Sarabhai Enterprises Limited
BSE: AMBALALSA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Ambalal Sarabhai Enterprises Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ambalal Sarabhai Enterprises Ltd is a diversified company engaged in the manufacturing and marketing of pharmaceutical products, molecular diagnostics, and electronics. The company operates through various group entities to serve both domestic and international markets.
Business Model
The company generates revenue by leveraging its group structure to produce and distribute healthcare and electronic goods. It focuses on a B2B and B2C approach across its pharmaceutical and diagnostic product portfolios.
Growth Outlook
Growth is expected to be driven by the continued expansion of its pharmaceutical and molecular diagnostic offerings. The company aims to maintain its market presence by capitalising on its established manufacturing capabilities.
Key Risks
- Regulatory Compliance. The pharmaceutical and diagnostics sectors are subject to stringent government regulations and quality control standards that may impact operational costs.
- Market Competition. The company faces intense competition from both domestic and multinational players in the healthcare and electronics industries.
- Technological Obsolescence. Rapid advancements in molecular diagnostics and electronics require continuous investment in research and development to remain competitive.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for pharmaceutical and electronic manufacturing could affect profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Ambalal Sarabhai Enterprises Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹202 Cr
TTM · consolidated
NET PROFIT
₹19 Cr
TTM · consolidated
EPS
₹2.39
TTM · consolidated
RETURN ON EQUITY
13.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.0%
TTM · consolidated
P/E
13.1x
Q4 FY26 · consolidated
EV/EBITDA
9.3x
Q4 FY26 · consolidated
EBITDA MARGIN
13.3%
TTM · consolidated
NET PROFIT MARGIN
9.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Ambalal Sarabhai Enterprises LimitedAMBALALSA | ₹337 Cr | 18.41 | 14.21 | -3.6% | 13.3% | 13.1% | 14.0% | +40.2% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Ambalal Sarabhai Enterprises Limited
BSE: AMBALALSA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Ambalal Sarabhai Enterprises Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ambalal Sarabhai Enterprises Ltd is a diversified company engaged in the manufacturing and marketing of pharmaceutical products, molecular diagnostics, and electronics. The company operates through various group entities to serve both domestic and international markets.
Business Model
The company generates revenue by leveraging its group structure to produce and distribute healthcare and electronic goods. It focuses on a B2B and B2C approach across its pharmaceutical and diagnostic product portfolios.
Growth Outlook
Growth is expected to be driven by the continued expansion of its pharmaceutical and molecular diagnostic offerings. The company aims to maintain its market presence by capitalising on its established manufacturing capabilities.
Key Risks
- Regulatory Compliance. The pharmaceutical and diagnostics sectors are subject to stringent government regulations and quality control standards that may impact operational costs.
- Market Competition. The company faces intense competition from both domestic and multinational players in the healthcare and electronics industries.
- Technological Obsolescence. Rapid advancements in molecular diagnostics and electronics require continuous investment in research and development to remain competitive.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for pharmaceutical and electronic manufacturing could affect profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Ambalal Sarabhai Enterprises Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹202 Cr
TTM · consolidated
NET PROFIT
₹19 Cr
TTM · consolidated
EPS
₹2.39
TTM · consolidated
RETURN ON EQUITY
13.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.0%
TTM · consolidated
P/E
13.1x
Q4 FY26 · consolidated
EV/EBITDA
9.3x
Q4 FY26 · consolidated
EBITDA MARGIN
13.3%
TTM · consolidated
NET PROFIT MARGIN
9.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26